These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 35498548)

  • 21. Molecular targets and system biology approaches for drug repurposing against SARS-CoV-2.
    Singh RK; Yadav BS; Mohapatra TM
    Bull Natl Res Cent; 2020; 44(1):193. PubMed ID: 33230386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brief considerations on targeting RNA with small molecules.
    Vicens Q; Westhof E
    Fac Rev; 2022; 11():39. PubMed ID: 36644293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Applying polypharmacology approach for drug repurposing for SARS-CoV2.
    Jamir E; Sarma H; Priyadarsinee L; Nagamani S; Kiewhuo K; Gaur AS; Rawal RK; Murugan NA; Subramanian V; Sastry GN
    J Chem Sci (Bangalore); 2022; 134(2):57. PubMed ID: 35498548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polypharmacology guided drug repositioning approach for SARS-CoV2.
    Jamir E; Sarma H; Priyadarsinee L; Kiewhuo K; Nagamani S; Sastry GN
    PLoS One; 2023; 18(8):e0289890. PubMed ID: 37556478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.
    Vijayan V; Pant P; Vikram N; Kaur P; Singh TP; Sharma S; Sharma P
    J Biomol Struct Dyn; 2021 Oct; 39(17):6713-6727. PubMed ID: 32741322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an
    Khan RJ; Jha RK; Singh E; Jain M; Amera GM; Singh RP; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022 Jan; 40(1):438-448. PubMed ID: 32885740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repurposing FDA-approved drugs to fight COVID-19 using
    Mahdian S; Zarrabi M; Panahi Y; Dabbagh S
    Inform Med Unlocked; 2021; 23():100541. PubMed ID: 33649734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease.
    Chowdhury KH; Chowdhury MR; Mahmud S; Tareq AM; Hanif NB; Banu N; Reza ASMA; Emran TB; Simal-Gandara J
    Biology (Basel); 2020 Dec; 10(1):. PubMed ID: 33374717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coronaviral RNA-methyltransferases: function, structure and inhibition.
    Nencka R; Silhan J; Klima M; Otava T; Kocek H; Krafcikova P; Boura E
    Nucleic Acids Res; 2022 Jan; 50(2):635-650. PubMed ID: 35018474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase.
    Newman JA; Douangamath A; Yadzani S; Yosaatmadja Y; Aimon A; Brandão-Neto J; Dunnett L; Gorrie-Stone T; Skyner R; Fearon D; Schapira M; von Delft F; Gileadi O
    Nat Commun; 2021 Aug; 12(1):4848. PubMed ID: 34381037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Length of remdesivir treatment in patients with severe COVID-19.
    Ippolito M; Cortegiani A
    Breathe (Sheff); 2021 Mar; 17(1):200276. PubMed ID: 34295393
    [No Abstract]   [Full Text] [Related]  

  • 32. Structural Analysis of the OC43 Coronavirus 2'-O-RNA Methyltransferase.
    Dostalik P; Krafcikova P; Silhan J; Kozic J; Chalupska D; Chalupsky K; Boura E
    J Virol; 2021 Jul; 95(15):e0046321. PubMed ID: 34011548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
    Menni C; Klaser K; May A; Polidori L; Capdevila J; Louca P; Sudre CH; Nguyen LH; Drew DA; Merino J; Hu C; Selvachandran S; Antonelli M; Murray B; Canas LS; Molteni E; Graham MS; Modat M; Joshi AD; Mangino M; Hammers A; Goodman AL; Chan AT; Wolf J; Steves CJ; Valdes AM; Ourselin S; Spector TD
    Lancet Infect Dis; 2021 Jul; 21(7):939-949. PubMed ID: 33930320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System.
    Banoun H
    Nephron; 2021; 145(4):392-403. PubMed ID: 33910211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Towards developing a criterion to characterize non-covalent bonds: a quantum mechanical study.
    Kumar N; Saha S; Sastry GN
    Phys Chem Chem Phys; 2021 Apr; 23(14):8478-8488. PubMed ID: 33876011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity.
    Kumar S; Singh B; Kumari P; Kumar PV; Agnihotri G; Khan S; Kant Beuria T; Syed GH; Dixit A
    Comput Struct Biotechnol J; 2021; 19():1998-2017. PubMed ID: 33841751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coronavirus genomic nsp14-ExoN, structure, role, mechanism, and potential application as a drug target.
    Tahir M
    J Med Virol; 2021 Jul; 93(7):4258-4264. PubMed ID: 33837972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repurposing of approved drug molecules for viral infectious diseases: a molecular modelling approach.
    Kumar N; Sarma H; Sastry GN
    J Biomol Struct Dyn; 2022 Oct; 40(17):8056-8072. PubMed ID: 33810775
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.